Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL -- Ignore unavailable to you. Want to Upgrade?

To: John Grabiec who wrote (1372)	5/11/1998 9:09:00 AM
From: SIer formerly known as Joe B.	Read Replies (1) \| Respond to of 1704

VIMRX Names Paul M. Simon, Ph.D., Vice President of Research Business Wire - May 11, 1998 08:26 %VIMRX VMRX %DELAWARE %MEDICINE %PHARMACEUTICAL %MANAGEMENT %CHANGES V%BW P%BW Jump to first matched term WILMINGTON, Del.--(BW HealthWire)--May 11, 1998--VIMRX Pharmaceuticals Inc. (NASDAQ:VMRX) announced today the appointment of Paul M. Simon, Ph.D., 47, as vice president of Research, effective May 18, 1998. Dr. Simon joins VIMRX with a strong background in cellular immunology and cell therapy, and extensive experience in managing in-house and extramural research programs and collaborations. Dr. Simon's responsibilities will involve technology evaluation and project management for VIMRX and its portfolio companies. "Dr. Simon's background in cellular immunology is an excellent fit with VIMRX's primary focus in cell therapies, through our majority-owned subsidiary, Nexell Therapeutics, Inc.," said Dr. David A. Jackson, VIMRX executive vice president and chief scientific officer. "He will further strengthen VIMRX and Nexell's capabilities in the centrally important area of R&D and commercial development." Dr. Simon most recently served as director of drug development at Neose Technologies, Inc., where he was responsible for pre-clinical R&D in the areas of cell biology, microbiology, immunology and pharmacology for both pharmaceutical and nutritional products. Dr. Simon also played an integral role in defining the company's clinical development strategies. Previously, Dr. Simon served at DuPont and The DuPont Merck Pharmaceutical Company, where he was group leader for cellular immunotherapy research. In this position, he had the primary responsibility for the cell biology component of DuPont's Stericell(R) cellular immunotherapy business initiative. Dr. Simon and his group worked extensively with one of cellular therapy's pioneers, Dr. Steven A. Rosenberg of the NCI, on Dr. Rosenberg's LAK (Lymphokine Activated Killer cells) and TIL (Tumor Infiltrating Lymphocytes) programs and produced many of the cell populations that were administered to patients in Dr. Rosenberg's TIL clinical trials. Dr. Simon received his B.S. degree from the City College of New York and his Ph.D. from Syracuse University. He performed post- doctoral work at both UCLA and the Dana Farber Cancer Institute of Harvard Medical School. VIMRX Pharmaceuticals Inc. VIMRX Pharmaceuticals Inc. (NASDAQ: VMRX) is a biotechnology company developing innovative technologies to improve human health. VIMRX's portfolio will include three majority owned subsidiaries: Nexell Therapeutics Inc., a company formed with Baxter Healthcare Corporation focused on cell therapeutics for cancer and other life threatening diseases; Innovir Laboratories, Inc. (NASDAQ: INVR), which develops oligozymes for use as both therapeutics and as pharmaceutical research tools; and, upon completion, Ventiv BioGroup, a biotechnology development company formed with Columbia University focused on research and development programs in the areas of cancer, diabetes, cardiovascular disease, wound healing and skin diseases. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward- looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company's periodic reports on Form 10-K and 10-Q, and any prospectus describing the Company's securities. NOTE TO INVESTORS AND EDITORS: VIMRX's press releases are available on the Internet through www.vimrx.com and through BusinessWire's web site at businesswire.com. The releases also are available at no charge through BusinessWire's fax-on-demand service at 800-411-8792. CONTACT: VIMRX Pharmaceuticals Media: Laura A. Mastrangelo 302-998-1734/800-916-8038 or The Investor Relations Group Investor: Dian Griesel, Ph.D. 212-664-8489